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CHAPTER I 
RESPIRATORY DISTRESS SYNDROMES 
1.1 Definition 
Respiratory distress syndromes consist of two major diseases both associated with lung 
failure. These include two forms identified as IRDS and ARDS. IRDS shape (or infant 
respiratory distress syndrome) is a congenital disorder that is highly frequent in preterm 
birth cases. In fact, lung has not yet acquired the ability to synthesize apoproteins of 
surfactant thus leading to both inflammatory and apoptotic phenomenon involving 
oxidative lung parenchyma and damage the alveolar epithelium and vessel growth. Acute 
respiratory distress syndrome (ARDS) is a life-threatening pulmonary syndrome 
characterized by the acute growth of diffuse lung injury in the setting of a known insult 
such trauma, sepsis, pneumonia, transfusion, or aspiration (Figure 1). The clinical features 
of ARDS are hypoxemic respiratory failure requiring positive pressure ventilation and 
acute diffuse bilateral lung infiltrates on chest radiography (Figure 2). The diagnostic 
criteria for ARDS have evolved since the syndrome was first recognized in 1967 
(Ashbaugh et al., 1967) and were most recently updated in the 2012 Berlin Definition of 
ARDS.  
 
Figure 1. Normal anatomy of the lung compared to ARDS. 
 5 
A 
 
B 
 
Figure 2. X-rays of both healthy (A) and ARDS patient (B). 
 
1.2 Epidemiology and pathogenesis of ARDS 
 
ARDS is a common syndrome, with an annual US incidence of greater than 80 per 100,000 
population, and it occours especially in adults (Hudson and Steinberg, 1999). ARDS can be 
precipitated by either direct or indirect insult to the lung. Direct insults pertain pneumonia, 
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aspiration of gastric contents, pulmonary contusion, or inhalation of injurious gases. 
Indirect injury can occur as a result of systemic processes such as sepsis, pancreatitis, 
multiple trauma, or massive transfusion of blood products. Sepsis is the most frequent 
cause of ARDS in humans. Sepsis causes the highest mortality compared with other 
etiologies of ARDS (Hudson and Steinberg, 1999). Early deaths in ARDS are because of 
hypoxic respiratory failure and development of multiple organ failure, whereas deaths after 
2 weeks are usually attributable to progressive pulmonary dysfunction as a result of 
exuberant fibroproliferation and the development of nosocomial infection, most notably 
pneumonia (Dever and Johanson, 1995;Marshall et al., 2000). In the initial phase of ARDS 
(referred to as the exudative phase), direct or indirect insults generally result in injury to 
both the capillary endothelium and the alveolar epithelium (Bachofen and Weibel, 
1982;Anderson and Thielen, 1992) (Figure 3). Type I alveolar epithelial cells (AECs) 
comprise  >95% of the alveolar surface, and are particularly susceptible to injury. As a 
consequence of capillary endothelial and AEC injury, there is loss of alveolar-capillary 
barrier function and accumulation of protein-rich edema fluid within the pulmonary 
interstitium and alveolus (Ware and Matthay, 2000). Denuded epithelium is replaced by 
the formation of proteinaceous hyaline membranes.  
 
 
Figure 3. Anatomopathological findings in ARDS 
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The exudative phase of ARDS is temporally associated with influx of neutrophils within 
pulmonary capillaries, margination and adherence to the activated endothelium, followed 
by exuberant accumulation of polymorphonuclear leukocytes (neutrophils) (PMNs) in both 
interstitial and alveolar spaces (Steinberg et al., 1994) (Figure 3). Activated PMNs 
contribute to lung injury by releasing a variety of injurious molecules, including neutrophil 
elastase, metalloproteases, and other proteolytic enzymes, oxidants, and reactive nitrogen 
species (Lee and Downey, 2001;Abraham, 2003). In addition to PMNs, there is 
chemokine-dependent emigration of macrophages, which can amplify pulmonary injury by 
releasing inflammatory cytokines and apoptosis-inducing molecules (Lee and Downey, 
2001) (Figure 4).  
 
 
Figure 4. Alteration in the alveolar epithelium after inflammatory phenomenon.   
 
The fibroproliferative phase of ARDS occurs early after injury (within initial 3 days) and 
temporally overlaps with inflammatory events that interest the exudative phase. The 
alveolar space becomes engorged with proliferating mesenchymal cells, such as 
fibroblasts, myofibroblasts, and locally generated pluripotent mesenchymal progenitor 
cells (Chesnutt et al., 1997;Horowitz et al., 2006) (Figure 5). Type II AECs proliferate to 
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replace necrotic and apoptotic type I cells, and new blood vessels form within the 
provisional matrix. There is also evidence of thrombogenesis and impaired fibrinolytic 
activity, as indicated by the accumulation of fibrin in the distal airspaces, together with 
microthrombi in small pulmonary vessels (Idell et al., 1989; Abraham, 2000;Prabhakaran 
et al., 2003). In some patients, there is pronounced deposition of matrix components, 
including fibronectin and replacement of type III collagen by type 1 collagen (Chesnutt et 
al., 1997). An exuberant fibroproliferative response in patients with ARDS is associated 
with a requirement for prolonged mechanical ventilation and increased mortality (Martin et 
al., 1995;Marshall et al., 2000). 
 
 
Figure 5. Pathophysiological cascade of ARDS acute phase.  
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CHAPTER II 
ADRENOMEDULLIN 
2.1 Discovery and biochemistry 
Adrenomedullin (AM) was discovered in 1993 when Kitamura and her colleagues, 
monitoring the increased concentrations of cAMP in plates with human 
pheochromocytoma cells attempt, they isolated this peptide. To this molecule, known then 
as adrenomedullin, the authors attributed vasodilatator and hypotensive properties. The 
peptide is highly represented in blood and, in smaller quantities, also in urine, 
cerebrospinal and amniotic fluids. Human AM, consisting of 52 amino acids, has one 
intramolecular disulfide bond (Figure 6) (Kitamura et al., 2002).  
 
 
Figure 6. Adrenomedullin primary structure. 
 
The carboxy terminal Tyr was amidated. The carboxy terminal amide structure is often 
observed in other biologically active peptides. AM shares structural homology with CGRP 
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and amylin. As shown in Figure 3a, the sequence homology of AM with human CGRP 
(Morris et al., 1984) and amylin (Cooper et al., 1987), is not high, although they share a 
six-residue ring structure formed by an intramolecular disulfide linkage and the C-terminal 
amide structure. It should be noted that the 14 residue amino terminal extension in AM is 
not found in CGRP and amylin. AM may belong to the CGRP superfamily based on its 
slight sequence homology and similar pharmacological activities to CGRP. 
In addition to human AM, the amino acid sequence of AM has been elucidated in rat, 
canine, mouse, porcine, and bovine species. Porcine AM is nearly identical to the human 
peptide, with a single substitution (Gly for Asn) at position 40 (Kitamura et al., 1994). Rat 
AM has 50 amino acids, with 2 deletions and 6 substitutions compared with the human 
peptide (Sakata et al., 1993).  
A comparison of amino acid sequences from different species is shown in Figure 6. 
Among these species, the ring structure and carboxy terminal amide structure, both of 
which are essential for biological activity (Eguchi et al., 1994), seem to be well preserved. 
The precursor for human AM (human preproAM)is composed of 185 amino acids in 
length, including the AM sequence (Kitamura et al., 1993).  
The predicted sequence of proAM contains a Gly-Lys-Arg segment immediately adjacent 
to the C-terminal tyrosine residue of AM. GIy-X-Y, where X and Y are basic residues, can 
serve as signals for C-terminal amidation, a process in which the glycine residue donates 
an amide moiety to the free carboxylic acid group (Bradbury and Smyth, 1991). In addition 
to AM, proadrenomedullin (proAM) contains a unique twenty amino acid sequence 
followed by Gly-Lys-Arg, a typical amidation signal, in the N-terminal region. It is 
possible  that  a  novel  20  residue  peptide,  termed  “proadrenomedullin  N-terminal 20 peptide 
(PAMP)” whose carboxy terminus is Arg-CONH2, is processed from AM precursor. 
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 We have clarified that PAMP exists in vivo and elicits a potent hypotensive activity in 
anesthetized rats, as described in Proadrenomedullin N-Terminal 20 Peptide. In addition to 
human PAMP, the amino acid sequence of PAMP has been elucidated in rat, canine, 
mouse, porcine, and bovine species. Among these species, the amide structure and the 
amino acid sequences of PAMP in the C-terminal region seem to be well preserved, a 
requirement for hypotensive activity. 
The genes for human and mouse AM were isolated and its structure was determined 
(Okazaki et al., 1996). The genomic DNA of human AM consists of 4 exons and 3 introns. 
The mature AM peptide is coded in the fourth exon, while PAMP is interposed by the 
second intron. The 5  franking region of the AM gene contains TATA, CAAT, and CC 
boxes. These elements are regarded as essential to the initiation of transcription by RNA 
polymerase II and basal expression of the gene. In addition, there are several binding sites 
for activator protein-2 (AP-2)   in   the   5’   upstream   region   of   exon   1.   Because   AP-2 is 
assumed to mediate transcriptional activation induced by protein kinase C and cAMP, 
expression of the AM gene may be subject to these signal transduction pathways (Imagawa 
et al., 1987). Considering that AM stimulates platelet cAMP production, the multiple AP-2 
sites suggest the existence of a feed- back mechanism. In intron 1, there is a consensus 
sequence for the cAMP-regulated enhancer (CRE) (Fink et al., 1988). This may also be 
involved in the putative feedback regulation of AM gene expression by cAMP. It has also 
been found that there are nuclear factor-kB (NF-kB) sites on the promotor of the AM gene. 
A study of the functional elements of the AM gene demonstrated that the nuclear factor for 
interleukin-6 (NF-IL-6), AP-2, and the TATA box in this region are important in the 
transcription regulation of the gene. These indicate that the human AM gene contains 
components for its functional expression, and that the expression may be subject to the 
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activity of protein kinase C and feedback from cAMP levels. In addition, the AM gene is 
found to be situated in a single locus of chromosome. 
 
2.2 Molecular Characterization of AM Receptor 
 
Kapas et al. (1995) cloned the cDNA for a putative AM receptor (L1) from rat lung tissue. 
The cDNA for L1 encodes a polypeptide of 395 residues, which possesses seven putative, 
alpha-helical transmembrane domains and supposed members of the G-protein-linked 
receptor super family.  
The L1 receptor was identified as an orphan G protein-linked receptor that had been 
reported by two groups (Eva and Sprengel, 1993); (Harrison et al., 1993). When this 
putative receptor was expressed in COS-7 cells, a cAMP response to AM occurred.  
But no response was found in cells stimulated with CGRP. In addition to L1, they reported 
that the orphan receptor RDC-1 functions as a receptor for both CGRP and AM (Kapas and 
Clark, 1995). However, the results concerning both L1 and RCD-1 described by Kapas et 
al. (1995) have not been reproduced in other laboratories.  
Calcitonin receptor-like receptor (CRLR) was originally discovered as an orphan receptor 
that shows a 55% identity with calcitonin receptor.  
This receptor expressed in COS-7 cells did not bind with members of the calcitonin/CGRP 
family of peptides. However, Aiyar et al. (1996) showed that human CRLR maintained its 
stability as it was transfected into human embryonic kidney (HEK) 293 cells exhibiting the 
pharmacology of CGRP1 receptor. Meanwhile, cRNA from SK-N-MC cells that expressed 
CGRP receptors was found to induce a novel CGRP response in Xenopus oocytes. 
The protein was cloned as a receptor activity modifying protein (RAMP1) (McLatchie et 
al., 1998). It has 148 amino acids with a single transmembrane domain that conferred 
CGRP1 receptor activity to the oocytes. Co-expression of CRLR with RAMP1 was found 
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to create novel CGRP receptors, but expression of either protein alone was without effect. 
Furthermore, database searches have revealed two more RAMP proteins, RAMP2 and 
RAMP3, which share approximately 30% identity with RAMP1. Expression of RAMP2 or 
RAMP3 with CRLR leads to its expression as an AM receptor. RAMP2 and RAMP3 
appear indistinguishable in terms of AM binding.  
The RAMPs are required to transport CRLR to the plasma membrane. RAMP1 presents 
CRLR as a mature glycoprotein at the cell surface to form a CGRP receptor, whereas 
RAMP2 or RAMP3 transported receptors are core glycosylated and then become AM 
receptors. CRLR mRNA is extremely abundant in the rat lung and was shown to be 
associated with blood vessels by in situ hybridization studies. CRLR protein was also 
shown to be associated with vascular endothelial cells by immunocytochemistry.  
As to the distributions of RAMPs mRNA expression in the human, rat, and mouse, 
RAMP1 is abundantly expressed in the brain, fat, thymus, and spleen, and RAMP2 in the 
lung, spleen, fat, and aorta, while RAMP3 is most abundant in the kidney and lung and is 
expressed ubiquitously (McLatchie et al., 1998).  
Recently Kuwasako et al. (2000) clearly demonstrated that the CRLR is endocytosed 
together with RAMPs via clathrin-coated vesi cles, and both the internalized molecules are 
targeted to the degradative pathway.  
Another interesting protein, the receptor component factor (RCF), was cloned on the basis 
of its ability to potentiate the endogenous Xenopus oocyte CGRP receptor (Luebke et al., 
1996). RCF is a hydrophobic 146 amino acid protein obtained from guinea pig organ of 
Corti, which is a cytosolic protein with no similarity to RAMPs.  
It has been recently demonstrated that RCF is essential for signal transduction of CGRP 
and AM, and interacts with CRLR directly within the cells (Evans et al., 2000)Namely, a 
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functional AM or CGRP receptor, which consists of at least three proteins: CRLR, RAMP, 
and RCF, couples the receptor to the intracellular signal transduction pathway (Figure 7). 
 
Figure 7. Adrenomedullin receptor transduction mechanisms. 
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CHAPTER III 
AIM OF THE STUDY 
The purpose of the present study was to evaluate the biological effects of adrenomedullin 
in both an in vitro and in vivo model of respiratory distress. In particular, we focused our 
attention to oxidative stress and inflammatory mechanisms. 
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CHAPTER IV 
MATERIALS AND METHODS 
 
4.1 Cell culture and pharmacological treatments 
Human lung carcinoma A549 cells, used as a model of lung tissue cells considering the 
effect of LPS in ARDS, were purchased from ATCC. Cells were routinely cultured in 
DMEM containing 10% heat-inactivated fetal bovine serum (FBS; Lifescience 
Technology, Milan, Italy), 100 units/mL of penicillin, 100 μg/mL of streptomycin, and 
250 ng/mL of amphotericin B (Sigma Aldrich, Milan, Italy). Cells were incubated in 
humidified atmosphere of 5% carbon dioxide and 95% air at 37 °C. At 80% confluency, 
the cells were passaged using trypsin-EDTA solution (0.05% trypsin and 0.02% EDTA). 
During the study cells were treated with LPS (Sigma) (0.5 μg/ml) for 1 hour. In separate 
set of experiments, cells were treated with Adrenomedullin (Sigma) (0.5 and 1 ng/ml) in 
the presence or  absence of LPS. 
4.2 Cell viability evaluation cytofluorimetric analysis 
Cell   viability  was  assessd   by  Muse™  Count  &  Viability  Kit   (Catalog  No.  MCH100102,  
Millipore,  Milan,   Italy)  according   to  the  manufacture’s  guidelines. Briefly, 50 μL of cell 
suspension containing 1 x 106 cells/mL were mixed with 450 μL of Count & Viability 
Reagent. Cells were allowed to stain for 10 minutes at room temperature and samples were 
read  by  Muse™  Cell  Analyzer  (Millipore). 
 
4.3 Annexin V and dead cell evaluation by cytofluorimetric analysis 
Cell   apoptosis   was   evaluated   by   Muse™   Annexin   V   &   Dead   cell   kit   (Catalog   No.  
MCH100105,  Millipore,  Milan,  Italy)  according  to  the  manufacture’s  guidelines.  Briefly,  
100 μL  of  the  Muse™  Annexin  V  &  Dead  Cell Reagent to 100 μL of cell suspension. Such 
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preparation was mixed thoroughly by vortexing at a medium speed for 3 to 5 seconds and 
samples were allowed to stain for 20 minutes at room temperature in the dark. Samples 
were  read  by  Muse™  Cell  Analyzer  (Millipore). 
 
4.4 Reactive Oxygen Species evaluation by cytofluorimetric analysis 
Reactive oxygen species (ROS) were determined by Muse® Oxidative Stress Kit (Catalog 
No.   MCH100111)   according   to   the   manufacture’s   guidelines.   Briefly,   10   μL cell 
suspension was prepared in 1X Muse Assay Buffer and added to 190 μL of Muse® 
Oxidative Stress Reagent working solution. Samples were vortexed for 3 to 5 seconds and 
then incubated for 30 minutes at 37°C. Following incubations samples were read by 
Muse™  Cell  Analyzer  (Millipore) 
 
4.5 Glutathione measurement 
Oxidative stress in glutamate-treated cultures, in presence or absence of antioxidants, was 
evaluated by a colorimetric determination of GSH intracellular content. Briefly, cells were 
scraped off and lysed in 50 μM sodium phosphate buffer, pH 7.4. Protein concentration in 
cell extracts was determined by spectrophotometric analysis (Synergy HT, Biotek, Italy). 
Then, reduced glutathione intracellular content (GSH) was chemically determined by a 
colorimetric assay, as previously described. 
 
4.6 ERK1/2 phosphorylation assessment by in-cell western 
On Day 1, A549 (5000 cells/20 µl/well) were seeded in a clear bottomed, black walled 96-
well plate and grown for 24 h at 37°C/5% CO2. On Day 2, cells were treated  and hen fixed 
in 4% PFA by adding 20 µl of 12% PFA directly to the wells for 1 h at room temperature. 
The wells were washed three times with PBS (50 µl/well), permeabilized with PBS/0.1% 
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Triton X-100 (50 µl/well, three times, 2 mins each), and blocked in LI-COR buffer (50 
µl/well) for 2 hours at room temperature (or alternatively overnight at 4°C). The wells 
were then incubated with mouse anti-ERK1/2 or rabbit anti-phospho-ERK1/2 antibodies 
(1:200 for optimal signal-to-noise ratio, Cell Signalling) in LI-COR blocking buffer for 2 
hours at room temperature (20 µl/well) and subsequently washed with PBS/0.1% Tween-
20 (50 µl/well, three times). Infrared anti-mouse IRDye800CW and anti-rabbit 
IRDye700CW secondary antibodies (1: 200) in PBS/0.5% Tween-20 were then added (20 
µl/well). The plates were incubated for 1 hour at room temperature, and the wells were 
washed with PBS/0.1% Tween-20 (three times) and incubated in PBS (50 µl/well). The 
plates were covered with black seals and imaged on an Odyssey infrared scanner using 
microplate2 settings with sensitivity of 5 in both the 700 and 800 nm wavelength channels. 
Data were acquired by using Odyssey software, exported and analyzed in Excel 
(Microsoft, Redmond, WA). Results were expressed as ratio between total ERK1/2 and 
phospho-ERK1/2. 
 
4.7 RNA extraction and qRT-PCR 
RNA was extracted by Trizol reagent (Invitrogen, Carlsbad, CA, USA). First strand cDNA 
was then synthesized with Applied Biosystem (Foster City, CA, USA) reverse 
transcription reagent. Quantitative real-time PCR was performed in 7900HT Fast Real-
Time PCR System Applied Biosystems using the SYBR Green PCR MasterMix (Life 
Technologies, Milan, Italy). The specific PCR products were detected by the fluorescence 
of SYBR Green, the double stranded DNA binding dye. The relative mRNA expression 
level was calculated by the threshold cycle (Ct) value of each PCR product and normalized 
with that of GAPDH by using comparative 2–ΔΔCt method. 
 
 19 
 
4.8 Animals 
Male Sprague Dawley rats (200 g; Charles River, Milan, Italy) were housed in a controlled 
environment and provided with standard rodent chow and water. Animal care was in 
compliance with Italian regulations on protection of animals used for experimental and 
other scientific purpose (D.M. 116192) as well as with the EEC regulations (O.J. of E.C. L 
358/1 12/18/1986). 
 
 
4.9 Experimental groups 
Rats were randomized into four experimental groups: 
1) LPS + vehicle group. Rats received intratracheal instillation of LPS (1 mg/kg), and  the 
vehicle for AM (saline 0.9%w/v, (N = 10) 
2) LPS + ADM (200 ng/kg) group. Identical to the LPS + vehicle group but they were also 
administered AM intratracheally (200 ng/kg) (N = 10) 
3) LPS + ADM (400 ng/kg) group. Identical to the LPS + vehicle group but they were also 
administered AM intratracheally (400 ng/kg) (N = 10) 
4) Sham + vehicle group. Identical to the LPS + vehicle group but animals received 
intratracheal 
instillation of saline (0.9% w/v), instead of LPS, (N = 10). 
5) Sham + ADM group (200 ng/kg). Identical to the LPS + AM group but animals received 
intratracheal instillation of saline (0.9% w/v) instead of LPS, and were treated with AM 
(200 ng/kg) intratracheally (N = 10). 
6) Sham + ADM group (400 ng/kg). Identical to the LPS + AM group but animals received 
intratracheal instillation of saline (0.9% w/v) instead of LPS, and were treated with AM 
(400 ng/kg) intratracheally (N = 10). 
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Rats were killed 24h following LPS treatment in order to evaluate the early mechanisms 
involved in acute lung injury.  
 
4.10 Induction of lung injury by LPS 
Rats received a single intratracheal instillation of saline (0.9% w/v) or saline containing 
LPS (1 mg/kg body weight) at end-expiration in a volume of 100 μL and the liquid was 
followed immediately by 300 μL of air, to ensure delivery to the distal airways. 
 
 
4.11 Measurement of fluid content in lung 
The wet lung weight was measured by careful excision of the lung from other adjacent 
extraneous tissues. The lung was exposed for 48 h at 180°C and the dry weight was 
measured. Water content was calculated by subtracting dry weight from wet weight. 
 
4.12 Histological examination 
Excised lung were taken 24h after LPS injection were fixed for 1 week in 10% (w/v) PBS-
buffered formaldehyde solution at room temperature, dehydrated, using graded ethanol and 
embedded in Paraplast (Sherwood Medical, Mahwah, NJ, USA). The sections were 
prepared and stained by hematoxylin and eosin and observed using light microscopy 
 
 
4.13 Citokynes Proteome Profiler Array 
To conduct a Proteome Profiler  array experiment, lungs were rinsed twice with PBS, and 
Nonidet P-40 lysis buffer was added. Tissue homogenates were gently rocked for 30 min at 
4 °C and then centrifuged at 14,000_g  for 5 min (4 °C), and the supernatants were frozen 
at -80 °C. A total of 250 micrograms of protein was used for each array. To prevent 
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unspecific protein binding, arrays were blocked using 2% bovine serum albumin in PBS 
for 1 h at room temperature. Subsequently tissue homogenates were diluted with PBS 
containing 2% bovine serum albumin, and the arrays were incubated with the diluted 
samples overnight at 4 °C. The arrays were then washed three times for 10 min with a 
wash buffer as specified by the manufacturer. After another washing step both types of 
arrays were processed using a luminol-based reagent, which is used in combination with 
LiCor secondary antibodies (Carlo Erba, Milan, Italy). Subsequently, arrays were analyzex 
with LiCor array scanner. 
 
 
 
 
4.14 Statistical Analysis 
 
Statistics were aided by Graph Pad Prism. All results were expressed as mean ± standard 
error of mean (S.E.M.). P values less than 0.05 were considered significant. Biochemical 
data were analyzed by one-way ANOVA with Bonferroni Post-Hoc analysis. 
Concentration-response curve from isolated pulmonary arteries were compared by two-
way ANOVA. 
 
 
 
 
 
 
 
 22 
CHAPTER V 
RESULTS 
5.1 Cell Viability 
Our data suggest that LPS treatment for 1 hour resulted in a signficant (p<0.05) reduction 
of cell viability (Figure 8). Interestingly, ADM treatment resulted in a dose dependent 
effect on cell viability. In fact, we observed a significant (p<0.05) increase of cell viability 
with a dose of 0,5 ng/ml of ADM whereas 1 ng/ml resulted in a significant (p<0.05) 
worsening of viability. 
 
Figure 8. Cytofluorimetric analysis of cell viability. Experiments were performed in 
triplicate. Picture is representative of a single experiment. 
 
5.2 Apoptosis evaluation by cytofluorimetric Annexin V expression 
LPS treatment resulted in a significant (P<0.05) increase of apoptotic cell death compared 
to untreated cultured cells (Figure 9). Consistently with cell viability results, we showed a 
dose dependent effect of ADM on cell apoptosis. In fact, we observed a significant 
(p<0.05) decrease of apoptosis with a dose of 0,5 ng/ml of ADM whereas 1 ng/ml resulted 
in a significant (p<0.05) worsening of apoptotic cell death. 
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Figure 9. Cytofluorimetric analysis of cell apoptosis by Annexin V assay. Experiments 
were performed in triplicate. Picture is representative of a single experiment. 
 
5.3 Reactive Oxygen Species formation 
Figure 10 shows that LPS treatment resulted in a significant increase in ROS formation. 
ADM (0,5 ng/ml) resulted in a significant decrease of ROS formation whereas ADM (1 
ng/ml) exacerbated ROS formation when compared to untreated cell cultures. 
 
 
Figure 10. Cytofluorimetric analysis of intracellular ROS content. Experiments were 
performed in triplicate. Picture is representative of a single experiment. 
 
 
5.4 Reduced glutathione content measurement 
In order to further demonstrate the protective and antioxidant properties of ADM, we also 
determined the intracellular content of reduced GSH. Our data suggest that LPS treatment 
results in a significant (p<0.05) decrease of GSH compared to untreated cells (Figure 11). 
ADM (0,5 ng/ml) restored GSH content in LPS treated cells. By contrast, ADM (1 ng/ml) 
significanttly (p<0.05) reduced GSH content compared to LPS treatment alone. 
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Figure 11. Spectrophotometric analysis of intracellular GSH content. Experiments were 
performed in triplicate and results are presented as percentage of the control. (*P<0.05 
when compared to control; **P<0.05 when compared to LPS). 
 
 
5.5 ERK1/2 phosphorylation assessment by in-cell western 
In order to further evaluate the molecular mechanism underlying ADM treatment we 
evaluated the phosphorylation of ERK-1/2, which is known to be activated also following 
LPS treatment. This set of experiment showed a significant increase of ERK1/2 
phosphorylation following LPS treatment (Figure 6). Interestingly, ADM (0,5 ng/ml) 
treatment at was able to prevent ERK1/2 activation. No significant effect was observed on 
ERK-1/2 phosphorylation following ADM (1 ng/ml) when compared to LPS treatment 
alone. 
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Figure 12. In cell western for evaluation of pERK. Experiments were performed in 
triplicate on a 96 well plate. Three independent wells are represented in the picture for each 
treatment. Green fluorescent represents total ERK whereas red fluorescence indicated ERK 
phosphorylation. 
 
5.6 Inflammatory mediators gene expression 
Our data showed that LPS treatments results in a significant activation of the inflammatory 
response as measured by the increased gn of well established inflammatory gene such as 
IL-6 (Figure 13). TNF-alpha, IL-8, IL-1 beta and MCP-1. ADM (0,5 ng/ml) resulted in a 
significant reduction of the inflammatory response when compared to LPS treated cells. By 
contrast, ADM (1 ng/ml) exacerbated the inflammatory response when compared to LPS 
treated cells or untreated cell cultures.  
 
 
Figure 13. Real time PCR evaluating various inflammatory mediators gene expression. 
Results are expressed as fold of increase compared to relative controls. 
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5.7 Effects of AM on LPS-induced lung injury and fluid content 
 
Twenty-four hours after LPS administration the pulmonary lesions observed in rats 
consisted of multifocal areas of severe inflammation and parenchymal lesions (Figure 
14A). ADM (200 ng/kg) resulted in a significant reduction od lung injury whereas ADM 
(400 ng/kg) had no significant effect on parenchyma injury. Similarly, ADM (200 ng/kg) 
resulted in a significant reduction of lung edema as measured by wet/dry weight ratio when 
compared to LPS treated animals (Figure 14B).  
A 
 
B 
 
Figure 14. (A) Histopathological findings (H&E staining) of rat lungs following 
intratracheal injection of LPS in the presence or absence of adrenomedullin treatment at 
various concentrations. Sham operated animals were referred as controls. (B) Wet/Dry 
lung weight ratio determination for the assessment of lung edema formation. (*p<0.05 
when compared to control; **p<0.05 when compared to LPS). 
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5.8 Citokynes Proteome Profiler Array 
In order to further confirm the in vivo protective effects of ADM, on the basis of the in 
vitro results we performed a citokyne proteome profiler array. These set of experimets 
confirmed that the in vitro inflammatory mediators are also upregulate at protein levels in 
the animal model of acute lung injury (Figure 15). Furthermore, we also showed that ADM 
(200 ng/Kg) exhibithed anti-inflammatory properties as shown by reduction of IL-6. TNF-
alpha, IL-8, IL-1 beta and MCP-1. No significant effects were observed for ADM (400 
ng/Kg) when compared to LPS treated animals. 
 
 
 
Figure 15. Citokynes Proteome Profiler Array for the evaluation of inflammatory 
cytokines production. Each cytokyne is spotted in duplicate on each membrane and 
intensity was determined by image J software. 
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CHAPTER VI 
DISCUSSION  
This study examined the beneficial effect of ADM on LPS-induced pulmonary injury; in 
particular, our results indicate that ADM has strong antioxidant, anti-inflammatory and 
antiapoptotic properties both in vitro and in vivo in a dose dependent manner. ADM can 
play a master role in orchestrating differential regulation among tissues during 
inflammation because of its capacity to bind to multiple classes of receptors  and elicit 
different tissue responses in specific tissue sites. In essence, ADM is both a hormone and a 
cytokine. It can simultaneously regulate aspects of regional blood flow, immunological 
recruitment, and preferential nutrient use by tissues during the inflammatory response. 
Many of the responses of body tissues to an inflammatory insult are triggered and 
modulated by cytokines. Most relevant to the topic at hand is the tight relationship between 
proinflammatory cytokines, like TNF-a  and IL-1b , and ADM during the onset of systemic 
as well as localized tissue inflammatory response. In our LPS model, it has been shown 
that 
the cytokine network is capable of modulating the different phases of lung injury 
pathogenesis in a dose dependent manner. Among the several cytokines and chemokines 
that have been implicated in the pathogenesis of lung injury, particular relevance has been 
given to IL-1 and TNF-a . Recent studies suggest that ADM plays a role in the complex 
network of pulmonary cytokines. In vitro data showed that ADM inhibits cytokine-induced 
neutrophil chemoattractant secretion from lipopolysaccharide-stimulated rat alveolar 
macrophages, and suppress TNF-a production in IL-1b  stimulated Swiss 3T3 cells. An in 
vivo study demonstrates a significant suppression of pulmonary TGF-b 1 and IL-1b  
mRNA expression by aerosolized ADM [23]. In the present study, we confirm that the 
model of lung injury used leads to a substantial increase in the levels of TNF-a  and IL-1 in 
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the lung after LPS administration and we report by first time that the production of the pro-
inflammatory cytokines are significantly attenuated by the treatment with ADM with low 
dose. There is compelling evidence that endogenous NO plays a key role in physiological 
regulation of airway functions and is implicated in airway disease. In an inflammatory 
micro environment NO, and related compounds, are produced by a wide variety of 
residential and inflammatory cells in the respiratory system [27]. This reaction is catalyzed 
by iNOS in macrophages and epithelial, endothelial, and vascular smooth-muscle cells. 
This isoform is regulated at a pre-translational level and can be induced by 
proinflammatory cytokines, such as TNF-a , and IL-1b . 
 
 
 
Conclusions 
These data support the hypothesis that ADM is an inhibitor of LPS-induced lung injury and 
this protective effect is observed also by a significant reduction of the oedema formation, 
tissue damage and reduced content of inflammatory mediators. In conclusion, we 
hypothesize that the antiinflammatory properties of ADM may be related to its ability to 
decrease the production and expression of proinflammatory cytokines, as our work has 
demonstrated. This property leads us to imagine the existence of an intricate interaction 
between ADM and cytokines, leading to a modulation of inflammatory process associated 
with lung injury. 
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